Insuman Basal: Uses, Dosage & Side Effects
An intermediate-acting isophane (NPH) human insulin used for basal blood glucose control in type 1 and type 2 diabetes mellitus
Insuman Basal is an intermediate-acting human insulin preparation containing isophane (NPH) insulin produced by recombinant DNA technology. It is used in the treatment of diabetes mellitus in patients who require insulin to maintain normal blood glucose levels. The protamine-complexed insulin crystals dissolve slowly after subcutaneous injection, providing a gradual and sustained insulin release over approximately 11 to 20 hours. Insuman Basal is commonly used as a basal insulin to control blood sugar levels between meals and overnight, and it may be combined with rapid- or short-acting insulin preparations for comprehensive glycemic management. It is listed on the WHO Model List of Essential Medicines and is widely prescribed throughout Europe and internationally.
Quick Facts: Insuman Basal
Key Takeaways
- Insuman Basal is an intermediate-acting isophane (NPH) human insulin that provides basal blood glucose control for approximately 11 to 20 hours, helping manage blood sugar levels between meals and overnight.
- It is used in both type 1 and type 2 diabetes mellitus and can be combined with rapid-acting or short-acting insulin to create a comprehensive insulin regimen tailored to each patient.
- Hypoglycemia (low blood sugar) is the most common and most serious adverse effect; patients must learn to recognize symptoms and carry glucose for emergency treatment at all times.
- Insuman Basal must be injected subcutaneously (never intravenously) and injection sites should be rotated within the same body region to prevent lipodystrophy and ensure consistent absorption.
- The suspension must be gently resuspended before each injection until it appears uniformly milky-white; it should never be used if particles or clumps remain after mixing.
What Is Insuman Basal and What Is It Used For?
Insuman Basal contains the active substance insulin human in an isophane (also called NPH – Neutral Protamine Hagedorn) formulation. The insulin in Insuman Basal is produced using recombinant DNA technology in Escherichia coli, making it structurally identical to the insulin naturally produced by the human pancreas. The isophane formulation involves the complexation of insulin with protamine sulfate, which forms crystalline precipitates that dissolve slowly after subcutaneous injection. This controlled dissolution results in a gradual, sustained release of insulin into the bloodstream, classifying Insuman Basal as an intermediate-acting insulin preparation.
Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia (elevated blood glucose) resulting from defects in insulin secretion, insulin action, or both. In type 1 diabetes, the immune system destroys the insulin-producing beta cells of the pancreas, leading to absolute insulin deficiency. These patients are entirely dependent on exogenous insulin for survival. In type 2 diabetes, the body develops insulin resistance and/or progressive beta-cell dysfunction, which can eventually necessitate insulin therapy when oral antidiabetic medications alone no longer achieve adequate glycemic control. Insuman Basal is prescribed for both forms of diabetes when insulin treatment is clinically indicated.
Once injected subcutaneously, the protamine-insulin crystals in Insuman Basal begin to dissolve within approximately 60 minutes. The insulin then enters the bloodstream and binds to insulin receptors on the surface of target cells, particularly in skeletal muscle, adipose tissue, and the liver. Receptor activation triggers a cascade of intracellular signaling events, including the translocation of GLUT4 glucose transporters to the cell membrane, which facilitates glucose uptake from the blood into cells. Simultaneously, insulin stimulates glycogen synthesis (glucose storage) in the liver and muscle, promotes lipogenesis (fat synthesis), and enhances protein synthesis. Crucially, insulin suppresses hepatic gluconeogenesis (glucose production by the liver), glycogenolysis (breakdown of stored glycogen), lipolysis (fat breakdown), and proteolysis (protein breakdown). The net result is a lowering of blood glucose levels and the promotion of anabolic metabolic processes.
The pharmacokinetic profile of Insuman Basal is characterized by an onset of action within approximately 60 minutes after subcutaneous injection, a peak effect between 3 and 4 hours post-injection, and a total duration of action of 11 to 20 hours. This duration varies depending on the dose administered, the injection site, blood flow at the injection site, the patient’s body temperature, and physical activity. The intermediate-acting profile makes Insuman Basal suitable for providing background (basal) insulin coverage – that is, insulin activity between meals and during the night to counteract the continuous release of glucose from the liver. Many patients use Insuman Basal in combination with a rapid- or short-acting insulin (such as Insuman Rapid or Insuman Infusat) administered at mealtimes to cover the postprandial glucose rise from food intake. This combination of basal and bolus insulin is often referred to as a basal-bolus regimen and closely mimics the physiological pattern of insulin secretion by a healthy pancreas.
Insuman Basal is available as a suspension for injection in several presentations, including vials for use with insulin syringes and prefilled cartridges for use with compatible insulin pen devices (such as the SoloStar pen). The standard concentration is 100 IU/ml, which is the most widely available formulation globally. A 40 IU/ml formulation is also available in certain markets. The choice of concentration and delivery system depends on regional availability, patient preference, and clinical considerations. Insulin is listed as an essential medicine by the World Health Organization (WHO), underscoring its fundamental importance in global healthcare.
Insuman Basal is designed to provide a slow, steady level of insulin between meals and overnight. Unlike rapid-acting insulins that handle blood sugar spikes after eating, Insuman Basal controls the baseline glucose production by the liver. Most patients inject it once or twice daily (typically at bedtime and/or in the morning), depending on their individual insulin requirements and the treatment plan established by their healthcare provider.
What Should You Know Before Taking Insuman Basal?
Contraindications
There are specific situations in which Insuman Basal must not be used. Understanding these contraindications is critical for patient safety.
- Hypersensitivity: Do not use Insuman Basal if you have a known allergy to insulin human or to any of the excipients, including protamine sulfate, metacresol, phenol, zinc chloride, sodium dihydrogen phosphate dihydrate, glycerol, sodium hydroxide, or hydrochloric acid. Allergic reactions to insulin can range from mild injection site reactions to severe, life-threatening anaphylaxis.
- Hypoglycemia: Insuman Basal must never be used to treat an episode of low blood sugar (hypoglycemia). Administering additional insulin during a hypoglycemic episode would further lower blood glucose to potentially dangerous or fatal levels. Instead, treat hypoglycemia with fast-acting glucose.
- Intravenous administration: Insuman Basal is formulated as an isophane suspension and must not be administered intravenously. The protamine-insulin crystals are designed for slow subcutaneous absorption; intravenous injection of the suspension would be dangerous and unpredictable.
- Insulin pumps: Insuman Basal must not be used in external or implanted insulin infusion pumps. Only soluble (clear) insulin preparations are suitable for pump use.
Warnings and Precautions
Hypoglycemia (low blood sugar) is the most frequent and potentially most serious adverse effect of insulin therapy. Severe hypoglycemia can cause loss of consciousness, seizures, brain damage, and death. Patients must learn to recognize early symptoms (sweating, trembling, hunger, rapid heartbeat, confusion, dizziness) and always carry a source of fast-acting glucose. If you cannot treat hypoglycemia yourself, someone should administer glucagon and call emergency services.
Before and during treatment with Insuman Basal, be aware of the following important precautions:
- Never switch insulin products without medical supervision. Switching between different types, brands, or concentrations of insulin can alter blood glucose control and increase the risk of hypoglycemia or hyperglycemia. Any change in insulin must be made cautiously and under the guidance of a healthcare provider, with increased blood glucose monitoring during the transition period.
- Injection site rotation: Rotate injection sites within the same anatomical region (abdomen, thigh, buttock, or upper arm) to reduce the risk of lipodystrophy (thickening or thinning of fat tissue under the skin) and cutaneous amyloidosis (lumps of protein under the skin). These conditions can impair insulin absorption, leading to unpredictable blood glucose levels.
- Kidney or liver disease: Insulin requirements may be reduced in patients with kidney or liver impairment because these organs play key roles in insulin clearance. Careful dose adjustment and more frequent blood glucose monitoring are necessary.
- Illness and stress: Infections, fever, surgery, trauma, and emotional stress typically increase insulin requirements. Blood glucose should be monitored more frequently during these periods, and insulin doses may need to be increased temporarily.
- Physical activity: Exercise increases insulin sensitivity and glucose uptake by muscles, which can lower blood sugar levels. Patients should monitor blood glucose before, during, and after exercise and may need to reduce insulin doses or consume additional carbohydrates.
- Alcohol consumption: Alcohol can both increase and prolong the blood-glucose-lowering effect of insulin and may impair the body’s ability to counteract falling blood glucose. Moderate alcohol intake only, and always with food.
- Driving and operating machinery: Hypoglycemia can impair concentration and reaction time. Patients should check their blood glucose before driving and at regular intervals during long journeys. Do not drive if blood glucose is low or if you feel hypoglycemic symptoms.
- Pioglitazone combination: Cases of cardiac failure have been reported when pioglitazone (a thiazolidinedione antidiabetic) was used in combination with insulin, particularly in patients with risk factors for heart failure. If you develop signs such as unusual weight gain, swelling, or shortness of breath, report them immediately.
Pregnancy and Breastfeeding
Insuman Basal can be used during pregnancy. Human insulin does not cross the placenta in clinically significant amounts. However, maintaining tight glycemic control throughout pregnancy is critically important because both hyperglycemia and hypoglycemia during pregnancy carry risks for both the mother and the developing baby. Poorly controlled diabetes in pregnancy is associated with an increased risk of congenital malformations, macrosomia (large baby), birth injuries, neonatal hypoglycemia, and preeclampsia.
Insulin requirements typically decrease during the first trimester of pregnancy and increase during the second and third trimesters. After delivery, insulin requirements usually fall rapidly back toward pre-pregnancy levels. Close monitoring by a specialist diabetes-in-pregnancy team is essential, with frequent blood glucose checks and regular dose adjustments throughout pregnancy and the postpartum period.
Women who are breastfeeding may require adjustments to their insulin doses and diet. Insulin does not pass into breast milk in a form that would affect the nursing infant, so breastfeeding is not contraindicated. However, the metabolic demands of lactation can lower maternal blood glucose levels, and dose reductions may be needed. Consult your healthcare team for personalized guidance.
Women who are planning a pregnancy should discuss their insulin regimen with their doctor well in advance, as optimal glucose control before conception significantly reduces the risk of pregnancy-related complications.
How Does Insuman Basal Interact with Other Drugs?
Insuman Basal, like all insulin preparations, interacts with a wide range of medications that can either enhance or diminish its blood-glucose-lowering effect. Some interactions increase the risk of hypoglycemia, while others may lead to hyperglycemia and loss of glycemic control. Understanding these interactions is essential for safe and effective diabetes management. Your doctor will consider all your medications when determining your insulin dose, and you should always inform your healthcare team about any changes in your medication regimen, including new prescriptions, over-the-counter drugs, and herbal supplements.
Drugs That May Increase the Blood-Glucose-Lowering Effect
The following medications can enhance insulin’s glucose-lowering action, increasing the risk of hypoglycemia. Dose adjustment of Insuman Basal and/or the interacting drug, along with more frequent blood glucose monitoring, may be necessary.
| Drug / Drug Class | Mechanism | Clinical Action |
|---|---|---|
| Oral antidiabetic agents (metformin, sulfonylureas, SGLT2 inhibitors) | Additive glucose-lowering effects through different pathways | Monitor blood glucose closely; adjust insulin or oral agent dose |
| ACE inhibitors (enalapril, ramipril, lisinopril) | May increase insulin sensitivity | Increased blood glucose monitoring when starting or adjusting |
| MAO inhibitors | May reduce insulin clearance and increase sensitivity | Close monitoring; potential insulin dose reduction |
| Salicylates (high-dose aspirin) | Increase peripheral glucose utilization | Monitor blood glucose; adjust doses as needed |
| Fibrates (fenofibrate, gemfibrozil) | May improve insulin sensitivity | Monitor and adjust insulin dose as needed |
| Fluoxetine | May enhance insulin action | Monitor blood glucose when starting or stopping |
| Alcohol | Inhibits hepatic gluconeogenesis; impairs counter-regulatory response | Avoid excessive intake; always consume with food |
Drugs That May Reduce the Blood-Glucose-Lowering Effect
| Drug / Drug Class | Mechanism | Clinical Action |
|---|---|---|
| Corticosteroids (prednisolone, dexamethasone) | Promote gluconeogenesis, reduce insulin sensitivity | Insulin dose may need significant increase; monitor closely |
| Thiazide diuretics (hydrochlorothiazide) | Impair insulin secretion and action | Monitor blood glucose; adjust insulin dose |
| Thyroid hormones (levothyroxine) | Increase hepatic glucose production | Monitor when initiating or adjusting thyroid replacement |
| Oral contraceptives / HRT | May increase insulin resistance | Monitor blood glucose when starting or stopping |
| Sympathomimetics (salbutamol, adrenaline, terbutaline) | Stimulate hepatic glucose output and glycogenolysis | Monitor blood glucose during acute use |
| Growth hormone (somatotropin) | Promotes insulin resistance | Adjust insulin dose; monitor glucose frequently |
| Atypical antipsychotics (olanzapine, clozapine) | May impair glucose metabolism and insulin sensitivity | Monitor for deterioration in glycemic control |
Drugs with Variable Effects on Blood Glucose
Beta-blockers deserve special attention. While they can enhance the glucose-lowering effect of insulin (increasing hypoglycemia risk), they also mask the typical warning symptoms of hypoglycemia, particularly tachycardia (rapid heartbeat) and tremor. This masking effect can delay recognition and treatment of hypoglycemia, making it especially dangerous. Patients using beta-blockers concurrently with insulin should be counseled about alternative hypoglycemic symptoms (such as sweating, which is not masked) and may require more frequent blood glucose monitoring.
Octreotide and lanreotide (somatostatin analogues) can both increase and decrease insulin requirements depending on the clinical situation. They suppress glucagon secretion (reducing blood glucose) but also inhibit insulin secretion and slow gastric emptying. The net effect is unpredictable and varies between individuals.
Whenever a new medication is started, stopped, or has its dose changed, blood glucose should be monitored more frequently for the first few days to weeks. This allows your healthcare team to adjust your insulin dose if necessary and prevents unexpected episodes of hypoglycemia or hyperglycemia.
What Is the Correct Dosage of Insuman Basal?
There is no universal standard dose for Insuman Basal. Insulin dosing is entirely individualized for each patient, based on blood glucose monitoring results, the type of diabetes, body weight, diet, exercise patterns, concurrent medications, and overall health status. Your doctor or diabetes specialist will determine the appropriate starting dose and guide you through any necessary adjustments. Self-adjustment of insulin doses should only be performed according to instructions provided by your healthcare team.
Adults
Type 1 Diabetes – Adults
The typical total daily insulin requirement is 0.5 to 1.0 IU per kilogram of body weight. In a basal-bolus regimen, approximately 40–50% of the total daily dose is given as Insuman Basal (basal component), usually once or twice daily (morning and/or bedtime). The remaining 50–60% is provided as rapid- or short-acting insulin at mealtimes.
Type 2 Diabetes – Adults
When insulin therapy is initiated in type 2 diabetes, the starting dose is typically 10 IU once daily (usually at bedtime) or 0.1 to 0.2 IU per kilogram of body weight. The dose is then titrated upward based on fasting blood glucose measurements, typically by 2–4 IU every 3–7 days until the target fasting glucose is achieved. Insuman Basal is often used alongside oral antidiabetic agents (such as metformin) or GLP-1 receptor agonists. Higher doses may be required over time due to progressive beta-cell decline.
Children
Pediatric Dosing
In children and adolescents with type 1 diabetes, the total daily insulin requirement varies widely by age and developmental stage. Prepubertal children typically require 0.7 to 1.0 IU/kg/day, while pubertal adolescents may require 1.0 to 2.0 IU/kg/day (or occasionally higher) due to growth-hormone-mediated insulin resistance. As with adults, Insuman Basal is used as the basal component, with rapid-acting insulin at meals. Dosing must be closely supervised by a pediatric endocrinologist, and frequent blood glucose monitoring is essential, as children can be more susceptible to hypoglycemia than adults.
Elderly
Dosing in Older Adults
In elderly patients, insulin requirements may be lower due to age-related decline in renal function and reduced hepatic insulin clearance. However, insulin resistance associated with aging can complicate dosing. A cautious, lower starting dose is generally recommended, with careful titration based on blood glucose monitoring. Hypoglycemia in elderly patients can be particularly dangerous, as it may present atypically (e.g., as confusion or falls rather than sweating or tremor) and may be more difficult to recognize. Glycemic targets may be relaxed in older adults with multiple comorbidities, limited life expectancy, or high vulnerability to hypoglycemia, in accordance with international diabetes guidelines.
Administration Technique
Insuman Basal is administered by subcutaneous injection. The preferred injection sites are the abdominal wall (fastest and most consistent absorption), the front of the thigh, the outer upper arm, and the buttock. Injection sites should be rotated within the same anatomical region to reduce the risk of lipodystrophy and ensure predictable insulin absorption. Injecting into a lump or area of skin thickening can cause unpredictable insulin absorption and erratic blood glucose control.
Before injection, the Insuman Basal suspension must be gently resuspended. For cartridges and prefilled pens, this is done by slowly inverting the pen up and down (or rolling it between the palms) at least 10 times until the suspension appears uniformly milky-white. Do not shake vigorously, as this can cause frothing and inaccurate dosing. If the suspension does not become uniformly white, or if visible clumps, particles, or flocculates remain after resuspension, do not use the product.
Missed Dose
If you miss a dose of Insuman Basal, check your blood glucose level immediately. Do not take a double dose to compensate for the missed injection, as this can cause severe hypoglycemia. If only a short time has passed since the missed dose, you may take it as soon as you remember, but adjust subsequent doses if needed to avoid stacking effects. Contact your doctor or diabetes nurse if you are unsure what to do. Keeping a regular injection schedule and using reminders can help prevent missed doses.
Overdose
An insulin overdose causes hypoglycemia, which can progress from mild symptoms (hunger, sweating, trembling, confusion) to severe manifestations (unconsciousness, seizures, coma, and death) if untreated. For mild hypoglycemia, immediately consume fast-acting glucose (e.g., glucose tablets, sugary drink). For severe hypoglycemia where the patient cannot eat or drink, administer glucagon injection and call emergency services immediately. After recovery from a severe episode, hospital observation is recommended. Repeated blood glucose monitoring and carbohydrate intake are essential to prevent recurrent hypoglycemia, as the intermediate-acting duration of Insuman Basal means the glucose-lowering effect can persist for many hours.
What Are the Side Effects of Insuman Basal?
Like all medicines, Insuman Basal can cause side effects, although not everybody gets them. The nature and severity of side effects depend on individual factors such as insulin dose, injection technique, diet, exercise, concurrent medications, and overall health. The most important side effect of insulin therapy is hypoglycemia, which can range from mild discomfort to a life-threatening emergency. Understanding and recognizing potential side effects allows for prompt management and safer insulin therapy.
Side effects are classified by frequency according to international conventions. Below is a comprehensive overview of the adverse effects associated with Insuman Basal based on clinical experience and post-marketing surveillance data.
Very Common
- Hypoglycemia – symptoms include sweating, trembling, hunger, rapid heartbeat, dizziness, confusion, blurred vision, headache, weakness, and irritability. Severe hypoglycemia can cause loss of consciousness, seizures, and coma.
Common
- Injection site reactions – redness, pain, itching, hives, swelling, or inflammation at the injection site. These are usually mild and temporary.
- Weight gain – insulin promotes glucose and fat storage, and weight gain is a known consequence of insulin therapy. Careful dietary management and exercise can help minimize this effect.
- Edema – fluid retention (swelling in feet, ankles, or hands) may occur, particularly at the start of insulin therapy or after an improvement in previously poor blood glucose control.
Uncommon
- Lipodystrophy – fatty tissue at the injection site may thicken (lipohypertrophy) or thin (lipoatrophy). Prevented by consistent rotation of injection sites. Injecting into affected areas causes unpredictable absorption.
- Cutaneous amyloidosis – skin lumps caused by amyloid protein deposits at frequently used injection sites. Like lipodystrophy, rotation of injection sites helps prevent this condition.
- Urticaria at injection site – hives localized to the injection area.
Rare
- Severe allergic reactions (anaphylaxis) – generalized skin reactions, angioedema (swelling of face, lips, tongue, or throat), bronchospasm, hypotension, and circulatory shock. This is a medical emergency requiring immediate treatment with epinephrine.
- Visual disturbances – temporary changes in vision may occur at the start of insulin therapy or with significant changes in blood glucose control. This is usually caused by temporary changes in the lens of the eye due to shifting fluid balances and typically resolves on its own.
- Diabetic retinopathy worsening – paradoxically, a rapid improvement in blood glucose control in patients with pre-existing diabetic retinopathy can occasionally lead to temporary worsening of retinopathy.
- Peripheral neuropathy – treatment-related neuropathy (painful neuropathy occurring with rapid improvement of glucose control) has been reported rarely with intensive insulin therapy.
- Anti-insulin antibodies – formation of antibodies against insulin may occasionally occur but rarely has clinical significance with human insulin preparations.
Hypoglycemia requires particular attention. Mild to moderate episodes (where the patient is conscious and able to self-treat) should be managed by immediately consuming 15–20 grams of fast-acting carbohydrate, such as glucose tablets, fruit juice, or a sugary drink. Blood glucose should be rechecked after 15 minutes, and treatment repeated if it remains below target. After blood glucose normalizes, a longer-acting carbohydrate snack (such as bread or crackers) should be eaten to prevent recurrence. Severe hypoglycemia (where the patient is unconscious or unable to swallow) requires glucagon injection by a trained companion or emergency intravenous glucose administration by healthcare professionals.
Patients should be aware that the warning symptoms of hypoglycemia may become less pronounced or change over time (a condition known as hypoglycemia unawareness). This is more common in patients with longstanding diabetes, autonomic neuropathy, and those who have had frequent previous episodes of hypoglycemia. Such patients are at increased risk of severe hypoglycemia without warning and require special attention from their healthcare team, including potentially relaxed glycemic targets.
Contact your doctor or seek emergency medical attention if you experience: severe hypoglycemia (unconsciousness, seizures, inability to eat or drink), signs of a generalized allergic reaction (widespread rash, difficulty breathing, rapid heartbeat, swelling of face or throat), or any unexpected or worsening side effect. Report all side effects to your healthcare provider.
How Should You Store Insuman Basal?
Proper storage of insulin is essential to ensure its efficacy and safety. Insulin that has been improperly stored may lose its potency, potentially leading to inadequate blood glucose control. Always check the appearance of the insulin before use and follow the storage guidelines carefully.
Before Opening
- Store in a refrigerator at 2°C to 8°C (36°F to 46°F).
- Keep the product in the outer carton to protect it from light.
- Do not place insulin directly against the freezer element or cooling packs.
- Do not freeze. If insulin has been accidentally frozen, it must be discarded. Freezing destroys the insulin protein structure and can alter the protamine crystals, making the product ineffective and potentially unsafe.
After Opening (In-Use)
- Once in use, Insuman Basal cartridges and prefilled pens may be stored at room temperature (below 25°C / 77°F) for a maximum of 21 days.
- Vials in use may be kept at room temperature (below 25°C) for up to 28 days.
- Keep the in-use pen or vial away from direct heat and sunlight. Do not store in a hot car, on a windowsill, or near a radiator.
- When using a pen, keep the cap on when not in use to protect the cartridge from light.
- Discard the product after the specified in-use period even if insulin remains, as sterility and stability can no longer be guaranteed.
Appearance Check
Before each injection, gently resuspend Insuman Basal and inspect its appearance. After proper mixing, the suspension should appear uniformly milky-white. Do not use the insulin if:
- The suspension does not become uniformly white after gentle mixing.
- Clumps, particles, or flocculates (flakes) are visible.
- The liquid appears clear (this may indicate that the protamine-insulin crystals have degraded).
- The product has been frozen.
- The expiry date has passed.
Keep all medicines, including insulin, out of the sight and reach of children. Do not dispose of unused insulin in household waste. Ask your pharmacist about proper disposal methods for used needles and expired insulin products.
What Does Insuman Basal Contain?
Active Ingredient
The active substance in Insuman Basal is insulin human, produced by recombinant DNA technology in Escherichia coli. The insulin is formulated as an isophane (NPH) suspension by complexation with protamine sulfate. Each milliliter of the 100 IU/ml formulation contains 100 International Units of insulin human, equivalent to approximately 3.5 mg of the insulin protein. The 40 IU/ml formulation contains 40 International Units per milliliter (approximately 1.4 mg).
Human insulin produced by recombinant DNA technology is structurally and functionally identical to the insulin secreted by the human pancreas. It consists of two polypeptide chains (A-chain of 21 amino acids and B-chain of 30 amino acids) connected by two disulfide bonds, with an additional intra-chain disulfide bond in the A-chain.
Inactive Ingredients (Excipients)
- Protamine sulfate – complexes with insulin to form the isophane crystals responsible for the intermediate duration of action
- Metacresol – antimicrobial preservative
- Phenol – antimicrobial preservative
- Zinc chloride – stabilizer that helps maintain the hexameric structure of insulin
- Sodium dihydrogen phosphate dihydrate – buffer to maintain appropriate pH
- Glycerol – tonicity adjusting agent (makes the solution isotonic with body fluids)
- Sodium hydroxide – pH adjuster
- Hydrochloric acid – pH adjuster
- Water for injections – solvent
Presentations
Insuman Basal is available in several presentations to suit different patient needs and preferences:
- Vials: 5 ml vials (containing 500 IU per vial at 100 IU/ml) for use with insulin syringes. Also available as 10 ml vials at 40 IU/ml (containing 400 IU per vial) in certain markets.
- Cartridges: 3 ml cartridges (containing 300 IU per cartridge at 100 IU/ml) for use with compatible reusable insulin pen devices.
- Prefilled pens (SoloStar): 3 ml prefilled disposable pens (containing 300 IU per pen at 100 IU/ml) that are ready to use and discarded after the insulin is depleted or 21 days after first use, whichever comes first.
Manufacturer
Insuman Basal is manufactured by Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany. The marketing authorization holder in Europe is Sanofi-Aventis Deutschland GmbH. Insuman Basal has been authorized by the European Medicines Agency (EMA) and is available in numerous countries worldwide.
Frequently Asked Questions About Insuman Basal
Insuman Basal and Insuman Rapid both contain human insulin but have very different time-action profiles. Insuman Basal is an intermediate-acting isophane (NPH) insulin that works slowly over 11 to 20 hours, providing background (basal) glucose control between meals and overnight. Insuman Rapid is a soluble (regular) insulin that acts quickly (within 30 minutes) and lasts only 5 to 9 hours, making it suitable for covering blood glucose rises after meals. Many patients use both together in a basal-bolus regimen for optimal diabetes control.
Insuman Basal should not be mixed with any other insulin or medicinal product unless specifically instructed by your doctor. If your healthcare provider directs you to mix Insuman Basal with Insuman Rapid (soluble insulin) in a syringe, the soluble insulin (clear) should always be drawn up first, followed by the isophane insulin (cloudy). The mixed insulin must be injected immediately after preparation. Pre-mixed insulin combinations (such as Insuman Comb) are available as alternatives if consistent mixing proves difficult. Never mix Insuman Basal with insulin analogues or non-human insulin products.
Blood glucose variability is normal and can be caused by many factors including differences in food intake (type, amount, and timing), physical activity levels, stress, illness, sleep quality, injection technique, injection site choice, and the natural biological variation in insulin absorption. The intermediate-acting profile of isophane insulin also has a more variable absorption pattern compared with some newer long-acting insulin analogues. Consistently using the same injection region (though rotating sites within that region), maintaining regular meal times, and keeping a blood glucose diary can help identify patterns and reduce variability.
If you accidentally inject too much Insuman Basal, eat a carbohydrate-rich food immediately (such as glucose tablets, fruit juice, or bread) and check your blood glucose frequently over the next several hours. Because Insuman Basal is intermediate-acting, the glucose-lowering effect can last up to 20 hours, so you may need to eat additional carbohydrates and monitor throughout this period. If you experience severe hypoglycemia symptoms (confusion, inability to eat, unconsciousness, seizures), someone should administer glucagon and call emergency services. Contact your doctor to discuss any dose adjustment.
Yes, but plan ahead. Carry your insulin in your hand luggage (never in checked luggage, as the cargo hold temperature can cause freezing). Use an insulated cooling case to protect the insulin from temperature extremes. Carry a letter from your doctor confirming your need for insulin and syringes/pens. When crossing time zones, discuss with your doctor how to adjust your injection schedule. Keep fast-acting glucose and glucagon readily accessible. Be aware that hot climates can accelerate insulin degradation, so avoid leaving insulin in direct sunlight or hot environments.
Modern long-acting insulin analogues (such as insulin glargine and insulin detemir) offer a flatter, more predictable absorption profile with a longer duration compared with NPH insulin like Insuman Basal. This means fewer blood glucose fluctuations and potentially fewer hypoglycemic episodes, especially overnight. However, Insuman Basal remains an effective, well-established, and more affordable option. The WHO lists human insulin (including NPH formulations) as an essential medicine. For many patients worldwide, human insulin provides excellent diabetes control when used appropriately. The choice between NPH insulin and analogues depends on individual clinical needs, patient preference, and availability.
References
- European Medicines Agency (EMA). Insuman Basal – Summary of Product Characteristics. Last updated 2025. Available from: EMA EPAR.
- American Diabetes Association (ADA). Standards of Care in Diabetes – 2025. Diabetes Care. 2025;48(Suppl 1). doi:10.2337/dc25-SINT.
- Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycaemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925–1966. doi:10.1007/s00125-022-05787-2.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023.
- Holt RIG, DeVries JH, Hess-Fischl A, et al. The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2021;44(11):2589–2625. doi:10.2337/dci21-0043.
- Rosenstock J, Bajaj HS, Janez A, et al. Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment. N Engl J Med. 2023;389(4):297–308. doi:10.1056/NEJMoa2303208.
- International Diabetes Federation (IDF). IDF Diabetes Atlas, 10th edition. Brussels: IDF; 2021.
- National Institute for Health and Care Excellence (NICE). Type 1 diabetes in adults: diagnosis and management. NICE guideline [NG17]. Updated 2022.
- National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management. NICE guideline [NG28]. Updated 2022.
- Sanofi-Aventis. Insuman Basal Package Leaflet: Information for the User. Current version.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in endocrinology, diabetology, and clinical pharmacology.
Medical Content
iMedic Endocrinology Editorial Team – specialist physicians in diabetes and endocrinology with clinical experience in insulin therapy
Medical Review
iMedic Medical Review Board – independent panel verifying accuracy against EMA SmPC, ADA Standards of Care, and EASD guidelines
Pharmacology Review
iMedic Clinical Pharmacology Team – specialists in drug interactions, pharmacokinetics, and medication safety
Accessibility & SEO
iMedic Digital Health Team – ensuring WCAG 2.2 AAA compliance and optimal search visibility
All content follows the GRADE evidence framework and is reviewed according to international medical guidelines. iMedic receives no commercial funding from pharmaceutical companies.